Compare Johnson Controls International PLC (JCI) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson Controls International PLC vs Tango Therapeutics Inc. — how do they compare? Johnson Controls International PLC trades at $153.19 (market cap $94.78B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: Johnson Controls International PLC is far larger — about 25.3× Tango Therapeutics Inc.'s market cap, and Johnson Controls International PLC pays a 1.02% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson Controls International PLC for 66 Days and Tango Therapeutics Inc. for 0 Days on average.
| JCI | TNGX | |
|---|---|---|
Market Cap | $94.78B | $3.75B |
Volume | 4,103,814 | 9,619,106 |
Sector | Basic Materials | Health |
52-Week High | $158.76 | $32.90 |
52-Week Low | $108.54 | $7.50 |
Typical Hold Time | 66 Days | 0 Days |
Enterprise Value | $103.61B | $2.77B |
Dividend Yield | 1.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson Controls International (JCI) trades at $152.44, down 1.91% on the day, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamentals with Q2 2026 EPS of $1.42 beating estimates of $1.30, maintaining a three-quarter beat streak. Revenue trends show recovery from $23.0B in 2024 to $23.6B in 2025, with net income margin expanding significantly to 13.94%. Recent news highlights strong Q3 2026 results with 10% organic sales growth and raised full-year guidance.
JCI presents a compelling investment case with analyst consensus strongly bullish (62% buy ratings) and a $172.50 price target offering 13% upside. Key opportunities include strong demand for data-center thermal management systems and expanding profit margins. Risks include elevated valuation multiples (P/E 44.08) and increasing debt-to-asset ratio (26.06% in 2025). The stock's technical position near key support at $153 requires monitoring for sustained bullish momentum.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson Controls International PLC
Johnson Controls manufactures, installs, and services HVAC systems, building management systems and controls, industrial refrigeration systems, and fire and security solutions. Commercial HVAC accounts for about 40% of sales, fire and security also represents 40% of sales, and residential HVAC, industrial refrigeration, and other solutions account for the remaining 20% of revenue. In fiscal 2021, Johnson Controls generated over $23.5 billion in revenue.
Read more on JCI →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
